These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16934456)

  • 1. N,N'-Diarylcyanoguanidines as antagonists of the CXCR2 and CXCR1 chemokine receptors.
    Nie H; Widdowson KL; Palovich MR; Fu W; Elliott JD; Bryan DL; Burman M; Schmidt DB; Foley JJ; Sarau HM; Busch-Petersen J
    Bioorg Med Chem Lett; 2006 Nov; 16(21):5513-6. PubMed ID: 16934456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 3,4-Diamino-2,5-thiadiazole-1-oxides as potent CXCR2/CXCR1 antagonists.
    Biju P; Taveras A; Yu Y; Zheng J; Chao J; Rindgen D; Jakway J; Hipkin RW; Fossetta J; Fan X; Fine J; Qiu H; Merritt JR; Baldwin JJ
    Bioorg Med Chem Lett; 2008 Jan; 18(1):228-31. PubMed ID: 18006311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological characterization of Sch527123, a potent allosteric CXCR1/CXCR2 antagonist.
    Gonsiorek W; Fan X; Hesk D; Fossetta J; Qiu H; Jakway J; Billah M; Dwyer M; Chao J; Deno G; Taveras A; Lundell DJ; Hipkin RW
    J Pharmacol Exp Ther; 2007 Aug; 322(2):477-85. PubMed ID: 17496166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluoroalkyl alpha side chain containing 3,4-diamino-cyclobutenediones as potent and orally bioavailable CXCR2-CXCR1 dual antagonists.
    Biju P; Taveras AG; Dwyer MP; Yu Y; Chao J; Hipkin RW; Fan X; Rindgen D; Fine J; Lundell D
    Bioorg Med Chem Lett; 2009 Mar; 19(5):1431-3. PubMed ID: 19196511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. C(4)-alkyl substituted furanyl cyclobutenediones as potent, orally bioavailable CXCR2 and CXCR1 receptor antagonists.
    Chao J; Taveras AG; Chao J; Aki C; Dwyer M; Yu Y; Purakkattle B; Rindgen D; Jakway J; Hipkin W; Fosetta J; Fan X; Lundell D; Fine J; Minnicozzi M; Phillips J; Merritt JR
    Bioorg Med Chem Lett; 2007 Jul; 17(13):3778-83. PubMed ID: 17459706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of potent and selective small-molecule antagonists for the CXCR2 chemokine receptor.
    Widdowson KL; Elliott JD; Veber DF; Nie H; Rutledge MC; McCleland BW; Xiang JN; Jurewicz AJ; Hertzberg RP; Foley JJ; Griswold DE; Martin L; Lee JM; White JR; Sarau HM
    J Med Chem; 2004 Mar; 47(6):1319-21. PubMed ID: 14998320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and structure-activity relationships of heteroaryl substituted-3,4-diamino-3-cyclobut-3-ene-1,2-dione CXCR2/CXCR1 receptor antagonists.
    Yu Y; Dwyer MP; Chao J; Aki C; Chao J; Purakkattle B; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Qiu H; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; He Z; Lai G; Wu M; Taveras A
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1318-22. PubMed ID: 18242983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2/CXCR1 receptor antagonist.
    Dwyer MP; Yu Y; Chao J; Aki C; Chao J; Biju P; Girijavallabhan V; Rindgen D; Bond R; Mayer-Ezel R; Jakway J; Hipkin RW; Fossetta J; Gonsiorek W; Bian H; Fan X; Terminelli C; Fine J; Lundell D; Merritt JR; Rokosz LL; Kaiser B; Li G; Wang W; Stauffer T; Ozgur L; Baldwin J; Taveras AG
    J Med Chem; 2006 Dec; 49(26):7603-6. PubMed ID: 17181143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diaminocyclobutenediones as potent and orally bioavailable CXCR2 receptor antagonists: SAR in the phenolic amide region.
    Aki C; Chao J; Ferreira JA; Dwyer MP; Yu Y; Chao J; Merritt RJ; Lai G; Wu M; Hipkin RW; Fan X; Gonsiorek W; Fosseta J; Rindgen D; Fine J; Lundell D; Taveras AG; Biju P
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4446-9. PubMed ID: 19525110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of a systemically-active dual CXCR1/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat.
    Garau A; Bertini R; Mosca M; Bizzarri C; Anacardio R; Triulzi S; Allegretti M; Ghezzi P; Villa P
    Eur Cytokine Netw; 2006 Mar; 17(1):35-41. PubMed ID: 16613761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2.
    Moriconi A; Cesta MC; Cervellera MN; Aramini A; Coniglio S; Colagioia S; Beccari AR; Bizzarri C; Cavicchia MR; Locati M; Galliera E; Di Benedetto P; Vigilante P; Bertini R; Allegretti M
    J Med Chem; 2007 Aug; 50(17):3984-4002. PubMed ID: 17665889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets.
    Bizzarri C; Beccari AR; Bertini R; Cavicchia MR; Giorgini S; Allegretti M
    Pharmacol Ther; 2006 Oct; 112(1):139-49. PubMed ID: 16720046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversing systemic inflammatory response syndrome with chemokine receptor pepducins.
    Kaneider NC; Agarwal A; Leger AJ; Kuliopulos A
    Nat Med; 2005 Jun; 11(6):661-5. PubMed ID: 15880119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of potent and orally bioavailable N,N'-diarylurea antagonists for the CXCR2 chemokine receptor.
    Jin Q; Nie H; McCleland BW; Widdowson KL; Palovich MR; Elliott JD; Goodman RM; Burman M; Sarau HM; Ward KW; Nord M; Orr BM; Gorycki PD; Busch-Petersen J
    Bioorg Med Chem Lett; 2004 Sep; 14(17):4375-8. PubMed ID: 15357956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Small molecule antagonists of the CXCR2 and CXCR1 chemokine receptors as therapeutic agents for the treatment of inflammatory diseases.
    Busch-Petersen J
    Curr Top Med Chem; 2006; 6(13):1345-52. PubMed ID: 16918453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Attenuation of murine allergic airway inflammation with a CXCR1/CXCR2 chemokine receptor inhibitor.
    Hosoki K; Rajarathnam K; Sur S
    Clin Exp Allergy; 2019 Jan; 49(1):130-132. PubMed ID: 30218547
    [No Abstract]   [Full Text] [Related]  

  • 17. [The role of CXCR1/2 in shear stress-induced endothelial cell migration].
    Sun H; Wei L; Liu X; Zeng Y; Lai Y; Yin H
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2009 Jun; 26(3):512-7. PubMed ID: 19634663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Boronic acid-containing aminopyridine- and aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous solubility and oral bioavailability.
    Schuler AD; Engles CA; Maeda DY; Quinn MT; Kirpotina LN; Wicomb WN; Mason SN; Auten RL; Zebala JA
    Bioorg Med Chem Lett; 2015 Sep; 25(18):3793-7. PubMed ID: 26248802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2.
    Nicholls DJ; Tomkinson NP; Wiley KE; Brammall A; Bowers L; Grahames C; Gaw A; Meghani P; Shelton P; Wright TJ; Mallinder PR
    Mol Pharmacol; 2008 Nov; 74(5):1193-202. PubMed ID: 18676678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New endogenous CXC chemokine ligands as potential targets in lung emphysema.
    Folkerts G; Kraneveld AD; Nijkamp FP
    Trends Pharmacol Sci; 2008 Apr; 29(4):181-5. PubMed ID: 18353448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.